Analgesia News and Research

RSS

Suggestions to reduce impact of anesthesia care on global warming

Inhaled anesthetics widely used for surgery—particularly the anesthetic desflurane—make a measurable contribution to global warming, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

Study finds increased neonatal mortality among planned home births

About 1 in 200 women in the US delivers her baby at home, with approximately 75% of these low-risk, single-baby births planned in advance as home deliveries. In a study published online today by the American Journal of Obstetrics & Gynecology (AJOG), researchers from Maine Medical Center, Portland, Maine, analyzed the results of multiple studies from around the world.

1 Jul 2010

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Anesthesia & Analgesia (A&A), official journal of the International Anesthesia Research Society (IARS), has achieved a significant increase in its Impact Factor, a key indicator of the influence and scientific value of medical journals, the IARS announced today.

29 Jun 2010

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Reporting in the journal Urology, researchers at Thomas Jefferson University have found that a pre-emptive multimodal pain regimen that included pregabalin (Lyrica) decreased the use of opioid analgesics in patients undergoing robotic-assisted laparoscopic radical prostatectomy.

28 Jun 2010

FDA approves Hospira's meropenem for injection, USP (I.V.)

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were approximately $200 million in 2009.

23 Jun 2010

Incline acquires IONSYS, announces $43 million Series A financing

Incline Therapeutics, Inc., a privately-held, hospital-focused specialty pharmaceutical company, announced today that it has entered into an agreement to acquire the rights to IONSYS™ (fentanyl iontophoretic transdermal system) from ALZA Corporation and completed a $43 million Series A financing.

22 Jun 2010

Cadence Pharmaceuticals to acquire Incline Therapeutics

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.

22 Jun 2010

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.

18 Jun 2010

DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results

DURECT Corporation announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR™ (also known as SABER™-bupivacaine or Optesia™ in the E.U.), a proprietary product under development for the treatment of post-surgical pain.

17 Jun 2010

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced today the full market release of its latest medical technology breakthrough—Masimo Rainbow Acoustic Monitoring— providing continuous and noninvasive respiration rate that is accurate, easy-to-use, and enhances patient tolerance.

7 Jun 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 –30 in Athens, Greece.

28 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Designation of operating rooms as "wet" locations could prevent electrical injury to patients, OR personnel

A frightening electrical injury to an operating room nurse highlights the need to update electrical safety policies for the operating room, according to the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

27 May 2010

Physician experts review current practices for pain management in cirrhotic patients

In the May issue of Mayo Clinic Proceedings, physician experts review current practices for pain management in cirrhotic patients. The physician experts reviewed all current literature available on PubMed and MEDLINE with no limits in the search to recommend a uniform and practical guide to approaching analgesia in the cirrhotic patients.

27 May 2010

Study assesses possible links between pain medications and recurrent breast cancer risk

Women who receive one common pain drug during mastectomy are less likely to develop recurrent breast cancer in the years following surgery, suggests a study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

27 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Early tracheotomy not beneficial in terms of MV duration, mortality compared to late tracheotomy

Early tracheotomy in ICU patients on mechanical ventilation (MV) did not reduce mortality when compared to later tracheotomy in a study of cardiac surgery patients requiring prolonged ventilation in a Paris study.

19 May 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Analgesia News and Research

Suggestions to reduce impact of anesthesia care on global warming

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Study finds increased neonatal mortality among planned home births

A&A journal achieves significant increase in Impact Factor; reflects scientific value of medical journals

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

FDA approves Hospira's meropenem for injection, USP (I.V.)

Incline acquires IONSYS, announces $43 million Series A financing

Cadence Pharmaceuticals to acquire Incline Therapeutics

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Masimo announces full market release of Rainbow Acoustic Monitoring to provide RRa

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Designation of operating rooms as "wet" locations could prevent electrical injury to patients, OR personnel

Physician experts review current practices for pain management in cirrhotic patients

Study assesses possible links between pain medications and recurrent breast cancer risk

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Early tracheotomy not beneficial in terms of MV duration, mortality compared to late tracheotomy

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News